# Moclobemide
*Source: https://go.drugbank.com/drugs/DB01171*

## Overview

### Description

This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.

### Background

A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs).  Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants
1
.

### Indication

For the treatment of major depressive disorder and bipolar disorder
1
.

### Pharmacodynamics

A selective, reversible inhibitor of monoamine oxidase (MAO) which increases the
1
. Besides its presence in sympathetic nerves, there is an abundant evidence that MAO-A is localized in noradrenergic neurons in the locus coeruleus and MAO-B is closely associated with serotonergic neurons of the raphe nucleus
1
.

### Mechanism of Action

Amine oxidase [flavin-containing] A
Antagonist
Inhibitor

### Absorption

Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first-pass metabolism reduces bioavailability to about 56% following administration of one dose, but increases to 90% with steady-state dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 0.3 - 1 hours following oral administration with a terminal half-life of 1.6h
4
.

### Metabolism

Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.
Moclobemide is a substrate of CYP2C19. Although it acts as an inhibitor of CYP1A2, CYP2C19, and CYP2D6
1
.
Hover over products below to view reaction partners
Moclobemide
Moclobemide M5
Moclobemide M6
Moclobemide M3
Moclobemide M1
Moclobemide M11
+
Moclobemide M13
+
Moclobemide M14
+
Moclobemide M15
+
Moclobemide M16
+
Moclobemide M18
Moclobemide M8
Moclobemide M4
Moclobemide M2
+
Moclobemide M7
Moclobemide M9

### Half-life

1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted

### Toxicity

LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures
3
. The effects of moclobemide alone in overdose are negligible, even with high volume ingestion.  However, moclobemide overdose with a serotonergic agent (even in small, therapeutic doses) can cause severe serotonin toxicity. The elimination half-life is prolonged by two to four times in overdose, compared with that found in healthy volunteers given therapeutic doses
3
.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Moclobemide is combined with 1,2-Benzodiazepine.
Abaloparatide
Moclobemide may increase the orthostatic hypotensive activities of Abaloparatide.
Abatacept
The metabolism of Moclobemide can be increased when combined with Abatacept.
Abciximab
The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Abciximab.
Abiraterone
The metabolism of Moclobemide can be decreased when combined with Abiraterone.

### Food Interactions

Avoid excessive or chronic alcohol consumption.
Avoid tyramine-containing foods and supplements. Avoid excess consumption (<100mg) of tyramine. Food that contains tyramine includes yogurt, aged cheese, ripe bananas, wine, and sourdough bread.
Take after a meal.

## Chemical Information

**DrugBank ID:** DB01171

**Synonyms:** 4-Chlor-N-(2-morpholinoethyl)benzamid
Moclobemid
Moclobemida
Moclobemide
Moclobemidum
p-Chloro-N-(2-morpholinoethyl)benzamide

**Chemical Formula:** C
13
H
17
ClN
2
O
2

**SMILES:** ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1

**Weight:** Average: 268.739
Monoisotopic: 268.097855505

**IUPAC Name:** 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

1

### Phase 0

0

### Phase 1

0

### Phase 2

2

### Phase 3

2

### Phase 4

1

### Therapeutic Categories

Antidepressive Agents Indicated for
Depression
Monoamine Oxidase
Inhibitors

### Summary

Moclobemide
is a monoamine oxidase inhibitor used in the treatment of major depressive disorder and bipolar disorder.

### Brand Names

Manerix

### Generic Name

Moclobemide

### DrugBank Accession Number

DB01171

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Moclobemide (DB01171)
×
Close

### External IDs

GNF-PF-695
RO 11-1163/000
RO-11-1163/000
RO-111163000

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Treatment of
Major depressive disorder
••••••••••••
Create Account
Create Account

### Mechanism of action

The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms
1
,
2
.
Target
Actions
Organism
A
Amine oxidase [flavin-containing] A
antagonist
inhibitor
Humans
U
Monoamine oxidase
antagonist
Humans
U
Amine oxidase [flavin-containing] B
antagonist
Humans

### Volume of distribution

1-1.5 L/Kg
4

### Protein binding

Approximately 50% (primarily to albumin)
4

### Route of elimination

Moclobemide is almost completely renally excreted
4
.

### Clearance

Clearance of 30-78  L/h
4
, mainly excreted in urine.

### International/Other Brands

Aurorix

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Manerix
Tablet
300 mg
Oral
Bausch Health, Canada Inc.
1995-12-31
Not applicable
Canada
Manerix
Tablet
150 mg
Oral
Bausch Health, Canada Inc.
1992-12-31
Not applicable
Canada
Manerix Tab 100mg
Tablet
100 mg / tab
Oral
Hoffmann La Roche
1992-12-31
1997-12-04
Canada
Moclobemide
Tablet
300 mg
Oral
Aa Pharma Inc
1999-07-14
Not applicable
Canada
Moclobemide
Tablet
150 mg
Oral
Aa Pharma Inc
1997-09-18
Not applicable
Canada

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Dom-moclobemide Tablets 150mg
Tablet
150 mg
Oral
Dominion Pharmacal
2001-02-15
2016-10-26
Canada
Dom-moclobemide Tablets 300mg
Tablet
300 mg
Oral
Dominion Pharmacal
2001-02-15
2016-10-26
Canada
Nu-moclobemide
Tablet
150 mg
Oral
Nu Pharm Inc
1998-07-28
2012-09-04
Canada
Nu-moclobemide
Tablet
100 mg
Oral
Nu Pharm Inc
1998-07-29
2012-09-04
Canada
PMS-moclobemide
Tablet
300 mg
Oral
Pharmascience Inc
2001-01-08
Not applicable
Canada

### ATC Codes

N06AG02 — Moclobemide
N06AG — Monoamine oxidase A inhibitors
N06A — ANTIDEPRESSANTS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Acids, Carbocyclic
Agents that produce hypertension
Agents that reduce seizure threshold
Amides
Antidepressive Agents
Antidepressive Agents Indicated for Depression
Benzamides and benzamide derivatives
Benzene Derivatives
Benzoates
Central Nervous System Agents
Central Nervous System Depressants
Chlorobenzoates
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2C19 inhibitors (strength unknown)
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2C9 Substrates
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)
Cytochrome P-450 CYP2D6 Substrates
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Enzyme Inhibitors
Monoamine Oxidase A Inhibitors
Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates
Monoamine Oxidase Inhibitors
Nervous System
Psychoanaleptics
Psychotropic Drugs
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Serotonin Agents
Serotonin Modulators

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
4-halobenzoic acids and derivatives
Alternative Parents
Benzamides
/
Benzoyl derivatives
/
Chlorobenzenes
/
Morpholines
/
Aryl chlorides
/
Trialkylamines
/
Secondary carboxylic acid amides
/
Amino acids and derivatives
/
Oxacyclic compounds
/
Dialkyl ethers
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Organic oxides
/
Hydrocarbon derivatives
show 5 more
Substituents
4-halobenzoic acid or derivatives
/
Amine
/
Amino acid or derivatives
/
Aromatic heteromonocyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Benzamide
/
Benzoyl
/
Carboxamide group
/
Carboxylic acid derivative
/
Chlorobenzene
/
Dialkyl ether
/
Ether
/
Halobenzene
/
Hydrocarbon derivative
/
Morpholine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Oxacycle
/
Oxazinane
/
Secondary carboxylic acid amide
/
Tertiary aliphatic amine
/
Tertiary amine
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
benzamides, monochlorobenzenes, morpholines (
CHEBI:83531
)

### Kingdom

Organic compounds

### Super Class

Benzenoids

### Class

Benzene and substituted derivatives

### Sub Class

Benzoic acids and derivatives

### Direct Parent

4-halobenzoic acids and derivatives

### Alternative Parents

Benzamides
/
Benzoyl derivatives
/
Chlorobenzenes
/
Morpholines
/
Aryl chlorides
/
Trialkylamines
/
Secondary carboxylic acid amides
/
Amino acids and derivatives
/
Oxacyclic compounds
/
Dialkyl ethers
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Organic oxides
/
Hydrocarbon derivatives
show 5 more

### Substituents

4-halobenzoic acid or derivatives
/
Amine
/
Amino acid or derivatives
/
Aromatic heteromonocyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Benzamide
/
Benzoyl
/
Carboxamide group
/
Carboxylic acid derivative
/
Chlorobenzene
/
Dialkyl ether
/
Ether
/
Halobenzene
/
Hydrocarbon derivative
/
Morpholine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Oxacycle
/
Oxazinane
/
Secondary carboxylic acid amide
/
Tertiary aliphatic amine
/
Tertiary amine
show 21 more

### Molecular Framework

Aromatic heteromonocyclic compounds

### External Descriptors

benzamides, monochlorobenzenes, morpholines (
CHEBI:83531
)

### Affected organisms

Humans and other mammals

### UNII

PJ0Y7AZB63

### CAS number

71320-77-9

### InChI Key

YHXISWVBGDMDLQ-UHFFFAOYSA-N

### InChI

InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)

### General References

Bonnet U: Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003 Spring;9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x. [
Article
]
Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K: Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7. doi: 10.1016/0009-9236(95)90230-9. [
Article
]
Isbister GK, Hackett LP, Dawson AH, Whyte IM, Smith AJ: Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol. 2003 Oct;56(4):441-50. [
Article
]
Monamine Oxidase Inhibitors [
Link
]
Citalopram [
Link
]

### External Links

Human Metabolome Database
HMDB0015302
KEGG Drug
D02561
PubChem Compound
4235
PubChem Substance
46504667
ChemSpider
4087
BindingDB
15613
RxNav
30121
ChEBI
83531
ChEMBL
CHEMBL86304
ZINC
ZINC000019606670
Therapeutic Targets Database
DAP000576
PharmGKB
PA452615
Wikipedia
Moclobemide

### Human Metabolome Database

HMDB0015302

### KEGG Drug

D02561

### PubChem Compound

4235

### PubChem Substance

46504667

### ChemSpider

4087

### BindingDB

15613

### RxNav

30121

### ChEBI

83531

### ChEMBL

CHEMBL86304

### ZINC

ZINC000019606670

### Therapeutic Targets Database

DAP000576

### PharmGKB

PA452615

### Wikipedia

Moclobemide

### Dosage Forms

Form
Route
Strength
Solution
Oral
100.000 mg
Tablet
Oral
Tablet, coated
Oral
150 mg
Tablet, film coated
Oral
Tablet
Oral
100 mg / tab
Tablet, film coated
Oral
150 MG
Tablet, film coated
Oral
300 MG
Tablet
Oral
150 mg
Tablet
Oral
150 mg / tab
Tablet
Oral
300 mg / tab
Tablet
Oral
100 mg
Tablet
Oral
300 mg

### Prices

Unit description
Cost
Unit
Manerix 300 mg Tablet
1.34USD
tablet
Apo-Moclobemide 300 mg Tablet
0.75USD
tablet
Novo-Moclobemide 300 mg Tablet
0.75USD
tablet
Pms-Moclobemide 300 mg Tablet
0.75USD
tablet
Manerix 150 mg Tablet
0.68USD
tablet
Apo-Moclobemide 150 mg Tablet
0.38USD
tablet
Novo-Moclobemide 150 mg Tablet
0.38USD
tablet
Pms-Moclobemide 150 mg Tablet
0.38USD
tablet
Apo-Moclobemide 100 mg Tablet
0.26USD
tablet
Novo-Moclobemide 100 mg Tablet
0.26USD
tablet
Nu-Moclobemide 100 mg Tablet
0.26USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
132
[L1357]
boiling point (°C)
377
[L1357]
water solubility
3.52e-04
[L1357]
logP
10.6
[L1357]
pKa
10.6 (ethanol-air)
[L1357]

### Predicted Properties

Property
Value
Source
Water Solubility
1.12 mg/mL
ALOGPS
logP
1.56
ALOGPS
logP
1.45
Chemaxon
logS
-2.4
ALOGPS
pKa (Strongest Acidic)
14.73
Chemaxon
pKa (Strongest Basic)
6.02
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
41.57 Å
2
Chemaxon
Rotatable Bond Count
4
Chemaxon
Refractivity
71.93 m
3
·mol
-1
Chemaxon
Polarizability
28.21 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9838
Blood Brain Barrier
+
0.9691
Caco-2 permeable
-
0.5602
P-glycoprotein substrate
Substrate
0.6652
P-glycoprotein inhibitor I
Inhibitor
0.6892
P-glycoprotein inhibitor II
Non-inhibitor
0.8637
Renal organic cation transporter
Non-inhibitor
0.5691
CYP450 2C9 substrate
Non-substrate
0.8538
CYP450 2D6 substrate
Non-substrate
0.9116
CYP450 3A4 substrate
Non-substrate
0.5723
CYP450 1A2 substrate
Non-inhibitor
0.9138
CYP450 2C9 inhibitor
Non-inhibitor
0.8989
CYP450 2D6 inhibitor
Non-inhibitor
0.8081
CYP450 2C19 inhibitor
Inhibitor
0.8024
CYP450 3A4 inhibitor
Non-inhibitor
0.9384
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.5956
Ames test
Non AMES toxic
0.6867
Carcinogenicity
Non-carcinogens
0.8727
Biodegradation
Not ready biodegradable
0.9844
Rat acute toxicity
2.6098 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.7135
hERG inhibition (predictor II)
Inhibitor
0.5646
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0fmr-7930000000-f5021f0bbc3af0c7125e
Mass Spectrum (Electron Ionization)
MS
splash10-0udi-2900000000-c3230d46878446405991
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-3436435ae42cfbae36f0
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-014i-0090000000-ebaa843d45c4c64c1d3d
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-00lr-0970000000-ab2fbe8b1feae9ff3141
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-e3243f45e1029a4c0e71
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-927950435244f3ac04e4
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-000i-0900000000-6fe640038cbc911e2bae
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-000i-0900000000-26e37ce9ba0b814b7409
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-014i-0090000000-07e0ca3dba489a2810ec
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-00lr-0980000000-70103607e1e68c966be9
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-ac7d3f04849dde0da3d2
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001r-0900000000-6634fb6b07312ce02ee6
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-000i-0900000000-c43f4a856e6d225766ef
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-000i-0900000000-1231bd387729155af4ab
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-a885de4ee2be84e3748d
MS/MS Spectrum - , positive
LC-MS/MS
splash10-00lr-0950000000-2942178c074461702181
MS/MS Spectrum - , positive
LC-MS/MS
splash10-0019-2900000000-bf1e7c693c96e9a69966
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-0290000000-389657d559087257f416
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014i-0290000000-d36276d4afe418710c2e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-03dr-1910000000-a812973a60da6c02988e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00pl-8950000000-c06cdf015556b47f7f4b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-06s9-0910000000-d55581dc79ab5f356585
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-001i-9220000000-0afc47571144e22a20a0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-0290000000-389657d559087257f416
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014i-0290000000-d36276d4afe418710c2e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-03dr-1910000000-a812973a60da6c02988e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00pl-8950000000-c06cdf015556b47f7f4b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-06s9-0910000000-d55581dc79ab5f356585
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-001i-9220000000-0afc47571144e22a20a0
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
166.3818777
predicted
DarkChem Lite v0.1.0
[M-H]-
156.05547
predicted
DeepCCS 1.0 (2019)
[M-H]-
166.3818777
predicted
DarkChem Lite v0.1.0
[M-H]-
156.05547
predicted
DeepCCS 1.0 (2019)
[M+H]+
166.8811777
predicted
DarkChem Lite v0.1.0
[M+H]+
158.44276
predicted
DeepCCS 1.0 (2019)
[M+H]+
166.8811777
predicted
DarkChem Lite v0.1.0
[M+H]+
158.44276
predicted
DeepCCS 1.0 (2019)
[M+Na]+
166.6011777
predicted
DarkChem Lite v0.1.0
[M+Na]+
164.5066
predicted
DeepCCS 1.0 (2019)
[M+Na]+
166.6011777
predicted
DarkChem Lite v0.1.0
[M+Na]+
164.5066
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Inhibitor

### General Function

Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues (PubMed:11049757, PubMed:11134050, PubMed:20493079, PubMed:8316221, PubMed:8665924). Preferentially degrades benzylamine and phenylethylamine (PubMed:11049757, PubMed:11134050, PubMed:20493079, PubMed:8316221, PubMed:8665924)

### Specific Function

electron transfer activity

### Gene Name

MAOB

### Uniprot ID

P27338

### Uniprot Name

Amine oxidase [flavin-containing] B

### Molecular Weight

58762.475 Da

